Yi-Chu Kao1,2, Wen-Liang Fang1,2, Ruei-Fang Wang3, Anna Fen-Yau Li2,4, Muh-Hwa Yang5,6, Chew-Wun Wu1,2, Yi-Ming Shyr1,2, Kuo-Hung Huang7,8. 1. Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei City, 11217, Taiwan. 2. School of Medicine, National Yang-Ming University, Taipei, Taiwan. 3. Department of Emergency Medicine, Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan. 4. Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan. 5. School of Medicine, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. 6. Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. 7. Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd., Beitou District, Taipei City, 11217, Taiwan. khhuang@vghtpe.gov.tw. 8. School of Medicine, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. khhuang@vghtpe.gov.tw.
Abstract
BACKGROUND: Signet ring cell adenocarcinoma is a histological classification based on the WHO classification. The presence of this specific histological type is associated with a worse pathological appearance. The prognosis of signet ring cell adenocarcinoma in gastric cancer patients after curative surgery is still under debate. METHODS: From January 1988 to December 2012, a total of 2971 patients, including 819 early and 2152 advanced gastric cancer patients underwent curative resection for gastric cancer. Among them, there were 185 cases of signet ring cell adenocarcinoma in early gastric cancer patients, while there were 570 cases in advanced gastric cancer patients. RESULTS: The overall incidence of signet ring cell adenocarcinoma was 25.4%. Our results showed that the 5-year overall survival rates of early gastric cancer patients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 90.7 and 83.2%, respectively (P = 0.001). The 5-year disease-free survival rates of early gastric cancer patients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 87.4 and 81.6%, respectively (P = 0.003). The 5-year overall survival rates of advanced gastric cancer patients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 32.1 and 37.9%, respectively (P = 0.041). The 5-year disease-free survival rates of advanced gastric cancer patients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 28.6 and 35.2%, respectively (P = 0.037). Signet ring cell adenocarcinoma was an independent predictor for overall survival in advanced gastric cancer (P = 0.017). CONCLUSION: The clinical features and prognosis of signet ring cell adenocarcinoma are different between early and advanced gastric cancer. Signet ring cell adenocarcinoma is a poor prognostic factor in advanced gastric cancer after curative resection.
BACKGROUND: Signet ring cell adenocarcinoma is a histological classification based on the WHO classification. The presence of this specific histological type is associated with a worse pathological appearance. The prognosis of signet ring cell adenocarcinoma in gastric cancerpatients after curative surgery is still under debate. METHODS: From January 1988 to December 2012, a total of 2971 patients, including 819 early and 2152 advanced gastric cancerpatients underwent curative resection for gastric cancer. Among them, there were 185 cases of signet ring cell adenocarcinoma in early gastric cancerpatients, while there were 570 cases in advanced gastric cancerpatients. RESULTS: The overall incidence of signet ring cell adenocarcinoma was 25.4%. Our results showed that the 5-year overall survival rates of early gastric cancerpatients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 90.7 and 83.2%, respectively (P = 0.001). The 5-year disease-free survival rates of early gastric cancerpatients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 87.4 and 81.6%, respectively (P = 0.003). The 5-year overall survival rates of advanced gastric cancerpatients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 32.1 and 37.9%, respectively (P = 0.041). The 5-year disease-free survival rates of advanced gastric cancerpatients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 28.6 and 35.2%, respectively (P = 0.037). Signet ring cell adenocarcinoma was an independent predictor for overall survival in advanced gastric cancer (P = 0.017). CONCLUSION: The clinical features and prognosis of signet ring cell adenocarcinoma are different between early and advanced gastric cancer. Signet ring cell adenocarcinoma is a poor prognostic factor in advanced gastric cancer after curative resection.
Entities:
Keywords:
Gastrectomy; Gastric cancer; Signet ring cell adenocarcinoma
Authors: Woo Jin Hyung; Sung Hoon Noh; Jun Ho Lee; Jihun J Huh; Ki Hyeok Lah; Seung Ho Choi; Jin Sik Min Journal: Cancer Date: 2002-01-01 Impact factor: 6.860
Authors: In Seob Lee; Sol Lee; Young Soo Park; Chung Sik Gong; Jeong Hwan Yook; Byung Sik Kim Journal: Surg Oncol Date: 2016-12-08 Impact factor: 3.279
Authors: Ulrike Heger; Susanne Blank; Christiane Wiecha; Rupert Langer; Wilko Weichert; Florian Lordick; Thomas Bruckner; Martin Dobritz; Maria Burian; Christoph Springfeld; Lars Grenacher; Jörg-Rüdiger Siewert; Markus Büchler; Katja Ott Journal: Ann Surg Oncol Date: 2014-01-14 Impact factor: 5.344
Authors: Zubin M Bamboat; Laura H Tang; Eduardo Vinuela; Deborah Kuk; Mithat Gonen; Manish A Shah; Murray F Brennan; Daniel G Coit; Vivian E Strong Journal: Ann Surg Oncol Date: 2014-01-07 Impact factor: 5.344